Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01109004
Other study ID # BMTCTN0702
Secondary ID BMT CTN 0702U01H
Status Completed
Phase Phase 3
First received
Last updated
Start date May 2010
Est. completion date March 3, 2018

Study information

Verified date December 2021
Source National Heart, Lung, and Blood Institute (NHLBI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy or single autologous transplant plus maintenance therapy as part of upfront treatment of multiple myeloma (MM). Lenalidomide will be used as maintenance therapy for three years in all arms.


Description:

The primary objective of the randomized trial is to compare three-year progression-free survival (PFS) between the three treatment arms as a pairwise comparison. Mobilization therapy will not be specified for the study. Randomization to three treatment arms will be done prior to the first transplants. All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive either a second autologous PBSC transplant with the same conditioning regimen as the first transplant or consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40 mg on Days 1, 8 and 15, and bortezomib 1.3mg/m^2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles) or maintenance with lenalidomide (15 mg daily). All patients will also receive maintenance lenalidomide which will start after the second transplant, after the first autologous transplant or after consolidation therapy depending on the treatment arm. Maintenance therapy with lenalidomide will start at 10 mg daily for three months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.


Other known NCT identifiers
  • NCT02257515

Recruitment information / eligibility

Status Completed
Enrollment 758
Est. completion date March 3, 2018
Est. primary completion date January 15, 2017
Accepts healthy volunteers No
Gender All
Age group N/A to 70 Years
Eligibility Inclusion Criteria: - Patients meeting the criteria for symptomatic multiple myeloma (MM). - Patients who are 70 years of age, or younger, at time of enrollment. - Patients who have received at least two cycles of any regimen as initial systemic therapy and are within 2 - 12 months of the first dose of initial therapy. - Cardiac function: left ventricular ejection fraction at rest greater than 40 percent. - Hepatic: bilirubin less than 1.5x the upper limit of normal and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 2.5x the upper limit of normal. (Patients who have been diagnosed with Gilbert's Disease are allowed to exceed the defined bilirubin value of 1.5x the upper limit of normal.) - Renal: Creatinine clearance of grater than or equal to 40 mL/min, estimated or calculated. - Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), or forced vital capacity (FVC) greater than 50 percent of predicted value (corrected for hemoglobin). - Patients with an adequate autologous graft defined as a cryopreserved PBSC graft containing greater than or equal to 4 x 10^6 CD34+ cells/kg patient weight. The graft may not be CD34+ selected or otherwise manipulated to remove tumor or other cells. The graft can be collected at the transplanting institution or by a referring center. The autograft must be stored so that there are two products each containing at least 2 x 10^6 CD34+ cells/kg patient weight. - Signed informed consent form. Exclusion Criteria: - Patients who never fulfill the criteria for symptomatic MM. - Patients with purely non-secretory MM [absence of a monoclonal protein (M protein) in serum as measured by electrophoresis and immunofixation and the absence of Bence Jones protein in the urine defined by use of conventional electrophoresis and immunofixation techniques]. Patients with light chain MM detected in the serum by free light chain assay are eligible. - Patients with plasma cell leukemia. - Karnofsky performance score less than 70 percent. - Patients with greater than grade 2 sensory neuropathy (CTCAE). - Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms). - Patients seropositive for the human immunodeficiency virus (HIV). - Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant. - Patient has hypersensitivity to bortezomib, boron or mannitol. - Patient has received other investigational drugs with 14 days before enrollment. - Patients with prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent less than 5 years previously will not be allowed unless approved by the Protocol Officer or one of the Protocol Chairs. Cancer treated with curative intent greater than 5 years previously is allowed. - Female patients who are pregnant (positive B-HCG) or breastfeeding. - Females of childbearing potential (FCBP) or men who have sexual contact with FCBP unwilling to use contraceptive techniques during the length of lenalidomide maintenance therapy. - Prior allograft or prior autograft. - Patients who have received mid-intensity melphalan (greater than 50 mg IV) as part of prior therapy. - Patients unable or unwilling to provide informed consent. - Prior organ transplant requiring immunosuppressive therapy. - Patients with disease progression prior to enrollment. - Patients who have received lenalidomide as initial therapy for MM and have experienced toxicities resulting in treatment discontinuation. - Patients who experienced thromboembolic events while on full anticoagulation during prior therapy with lenalidomide or thalidomide. - Patients unwilling to take deep vein thrombosis (DVT) prophylaxis. - Patients who cannot undergo an intervention in any treatment arm due to a priori denial of medical costs coverage by third party payers. - Patients unable to unwilling to return to the transplant center for their assigned treatments.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lenalidomide
All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
lenalidomide, bortezomib and dexamethasone
All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
Lenalidomide
All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.

Locations

Country Name City State
United States University of Michigan Medical Center Ann Arbor Michigan
United States Blood and Marrow Transplant Program at Northside Hospital Atlanta Georgia
United States Georgia Health Sciences University Augusta Georgia
United States St. Lukes Mountain States Tumor Institute Boise Idaho
United States DFCI, Brigham and Womens Hospital Boston Massachusetts
United States DFCI, Massachusetts General Hospital Boston Massachusetts
United States Roswell Park Cancer Center Buffalo New York
United States University of North Carolina Hospital at Chapel Hill Chapel Hill North Carolina
United States Rush University Medical Center Chicago Illinois
United States University of Illinois Chicago Illinois
United States Jewish Hospital BMT Program Cincinnati Ohio
United States University Hospitals of Cleveland Cleveland Ohio
United States Ohio State/Arthur G. James Cancer Hospital Columbus Ohio
United States University of Texas Southwestern Medical Center Dallas Texas
United States Colorado Blood Cancer Institute Denver Colorado
United States Karmanos Cancer Institute/BMT Detroit Michigan
United States City of Hope National Medical Center Duarte California
United States Duke University Medical Center Durham North Carolina
United States University of Florida College of Medicine Gainesville Florida
United States Hackensack University Medical Center Hackensack New Jersey
United States Penn State College of Medicine, The Milton S. Hershey Medical Center Hershey Pennsylvania
United States Baylor College of Medicine/The Methodist Hospital Houston Texas
United States University of Texas, MD Anderson CRC Houston Texas
United States University of Kansas Hospital Kansas City Kansas
United States Thompson Cancer Survival Center Knoxville Tennessee
United States UCSD Medical Center La Jolla California
United States North Shore University Hospital Lake Success New York
United States University of Kentucky Lexington Kentucky
United States University of Wisconsin Hospital & Clinics Madison Wisconsin
United States Medical College of Wisconsin Milwaukee Wisconsin
United States University of Minnesota Minneapolis Minnesota
United States West Virginia University Hospital Morgantown West Virginia
United States Sarah Cannon Blood & Marrow Transplant Program Nashville Tennessee
United States Vanderbilt University Medical Center Nashville Tennessee
United States Memorial Sloan-Kettering Cancer Center New York New York
United States Mount Sinai Medical Center New York New York
United States Christiana Care Health System Newark Delaware
United States University of Oklahoma Medical Center Oklahoma City Oklahoma
United States University of Nebraska Medical Center Omaha Nebraska
United States Florida Hospital Cancer Institute Orlando Florida
United States Advocate Lutheran General Hospital Park Ridge Illinois
United States University of Pennsylvania Cancer Center Philadelphia Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States University of Rochester Medical Center Rochester New York
United States Washington University, Barnes Jewish Hospital Saint Louis Missouri
United States Texas Transplant Institute San Antonio Texas
United States University of California, San Francisco San Francisco California
United States Fred Hutchinson Cancer Research Center Seattle Washington
United States Louisiana State University Health Sciences Center Shreveport Louisiana
United States Stanford Hospital and Clinics Stanford California
United States H. Lee Moffitt Cancer Center Tampa Florida
United States Arizona Cancer Center Tucson Arizona
United States Wichita CCOP Wichita Kansas
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (3)

Lead Sponsor Collaborator
National Heart, Lung, and Blood Institute (NHLBI) Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Soml — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Progression-free Survival (PFS) Progression-free survival is defined as survival without disease progression or initiation of non-protocol anti-myeloma therapy. To account for loss to follow-up of a few participants, the Kaplan-Meier estimator was used to estimate progression-free survival at 38 months post-randomization. 38 months post-randomization
Secondary Percentage of Participants With Disease Progression Disease Progression is defined as progression of multiple myeloma, including one or more of the following:
A reappearance of serum monoclonal paraprotein, with a level of at least 0.5 g/dL
24-hour urine protein electrophoresis with at least 200 mg paraprotein/24 hours
Abnormal free light chain levels of >10 mg/dl, only in patients without measurable paraprotein in the serum and urine
At least 10% plasma cells in a bone marrow aspirate or on trephine biopsy
Definite increase in the size of existing bone lesions or soft tissue plasmacytomas
Development of new bone lesions or soft tissue plasmacytomas
Development of hypercalcemia (corrected serum Ca >11.5 mg/dL or >2.8 mmol/L) not attributable to any other cause
To account for loss to follow-up of a few participants, the cumulative incidence of TRM at 38 months post-randomization was estimated using the Aalen-Johansen estimator, treating death prior to disease progression as a competing risk.
38 months post-randomization
Secondary Percentage of Participants With Overall Survival (OS) Overall survival is defined as survival of death from any cause. To account for loss to follow-up of a few participants, the Kaplan-Meier estimator was used to estimate overall survival at 38 months post-randomization. 38 months post-randomization
Secondary Percentage of Participants With Treatment-related Mortality (TRM) TRM is defined as death prior to progression of multiple myeloma. To account for loss to follow-up of a few participants, the cumulative incidence of TRM at 38 months post-randomization was estimated using the Aalen-Johansen estimator, treating disease progression as a competing risk. Up to 38 months post-randomization
Secondary Number of Participants With Treatment Response The number of participants with very good partial response (VGPR) or better [complete response (CR), near CR (nCR), and stringent CR (sCR)] according to the International Uniform Response Criteria will be calculated. The "Worse than VGPR" group includes PR, stable disease, and progressive disease.
sCR requires, in addition to CR: Normal free light chain ratio (FLC), Absence of clonal cells in bone marrow CR requires, in addition to nCR: Absence of the original monoclonal paraprotein (PPN), Disappearance of soft tissue plasmacytomas nCR is defined as: < 5% plasma cells in a bone marrow aspirate, No increase in lytic bone lesions VGPR requires: Serum or urine PPN not detectable on electrophoresis OR >=90% reduction in serum PPN plus urine PPN <100 mg/24hrs, >= 50% reduction in the level of serum monoclonal PPN or reduction in 24 hour urinary monoclonal PPN either >= 90% or to <200 mg/24 hours in light chain disease, >= 50% reduction in the size of soft tissue plasmacytomas
1 and 2 years post-randomization
Secondary FACT-G Total Score The Functional Assessment of Cancer Therapy-General (FACT-G) is a quality of life instrument that assesses the effects of cancer therapy on a patient's physical, social/family, emotional, and functional well-being. The assessment has 27 questions, each scored on a Likert scale from 0-4. The overall score is computed by adding scores of the questions and falls in the range 0-108, with higher scores indicating higher levels of overall well-being. Up to 3 years post-randomization
Secondary FACT-BMT Score The Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale (FACT-BMT) is a quality of life instrument that assesses the effects of bone marrow transplantation (BMT) on a patient's physical, social/family, emotional, and functional well-being while taking into consideration BMT-specific concerns. The assessment has 37 questions, each scored on a Likert scale from 0-4. The overall score is computed by adding scores of the questions and falls in the range 0-148, with higher scores indicating higher levels of overall well-being. Up to 3 years post-randomization
Secondary FACT-BMT Trial Outcome Index The Functional Assessment of Cancer Therapy (FACT) Trial Outcome Index is a quality of life instrument that assesses the impact of bone marrow transplantation (BMT) on a patient's physical and functional well-being while taking into consideration BMT-specific concerns. The assessment has 24 questions, each scored on a Likert scale from 0-4. The overall score is computed by adding scores of the questions and falls in the range 0-96, with higher scores indicating higher levels of overall well-being. Up to 3 years post-randomization
Secondary MOS SF-36 Physical Component Summary The Medical Outcome Study (MOS) SF-36 Physical Component Summary is a subscale of the SF-36 intended to measure physical well-being. It is scored on a scale of 0-100, with higher scores indicating higher levels of well-being. Up to 3 years post-randomization
Secondary MOS SF-36 Mental Component Summary The Medical Outcome Study (MOS) SF-36 Mental Component Summary is a subscale of the SF-36 intended to measure mental well-being. It is scored on a scale of 0-100, with higher scores indicating higher levels of well-being. Up to 3 years post-randomization
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1